4th Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Period 4th Quarter 2013 Filed Jan 20, 2014 Signed by Francesca Fierro O'Reilly

Official filing
Firm
AMERICAN CLINICAL LABORATORY ASSN
Client
AMERICAN CLINICAL LABORATORY ASSN
Income
—
Expenses
$278,322
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

TRICARE coverage of molecular pathology tests.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); SENATE; Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); White House Office; Office of Management & Budget (OMB)

Health Issues HCR

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Food & Drug Administration (FDA); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); White House Office; Defense, Dept of (DOD); SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Medicare Payment Advisory Commission (MedPAC); Defense, Dept of (DOD); SENATE; Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; Congressional Budget Office (CBO)

Budget/Appropriations BUD

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: SENATE; White House Office; Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Office of Management & Budget (OMB); Congressional Budget Office (CBO)

Medical/Disease Research/Clinical Labs MED

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); White House Office; Defense, Dept of (DOD); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.